TED is a severe eye disease leading in rare cases to decrease of sight, optic nerve compression and blindness. Recently, signifi cant progresses in understanding the disease have been done. Nevertheless, the treatment of the disease, especially in its severe form remains challenging. Glucocorticoids (GC) have been the basis of the treatment for a long time. Orbital irradiation (OI) and optical decompression (OD) are also used in managing the severe forms of TED. Somatostatin, intravenous immunoglobulin have been also used, with confl icting results. Regarding the potential for the treatment of TED with cytokine antagonists, controlled clinical studies are not available. Since cytokines play an important role in the pathogenesis of the TED, they seemed to be logical choice for modern TED treatment. It has been shown that both Th  (interleukin-, tumor necrosis factor γ, interleukin γ) and Th  (interleukin-,--,-) profi le T cells are activated in the TED. We therefore measured interleukin-γ, IF-γ and interleukin - (IL-)(Th  and Th  pattern) to assess its relationship to the course of the disease. Th is paper shows that both Th  (Il-) and Th  (If-γ) pathways represented by those two cytokines are not involved (Il- before ,±, and after treatment ,±,; IF γ before ,±, and after treatment ,±,). No relationship to the response to treatment was found. GC resulted in positive response in / patients, OI ( patients) given after CS therapy, resulted in a response in all patients. Increase in proptosis, loss of visual acuity is spite of CS treatment prompted OD in two patients, who both recovered visual acuity and proptosis fell under mm Hertel.
Introduction
Th e pathogenesis of TED is still not quite clear. It has long been proven that there is an increased volume of the extraocular muscles, as well as the increased orbital adipose and connective tissue. There is an increased concentration of glucosoamminogycans and a marked infi ltration with immunocompetent cells. T cells (mainly CD+), macrophages, B lymphocytes have been demonstrated in muscles, fat and connective orbital tissue. The general conception of the immune reactions in TED is as follows: auto reactive T lymphocyte recognize antigen(s) shared by the thyroid and the orbit, lymphocytes infi ltrate the tissues (facilitated by locally or circulated adhesion molecules (, ) , CD+ T lymphocytes secrete cytokines amplifying the immune reaction by activating CD+ T lymphocytes or antibody-producing T cells () . Both Th  (interleukin-, tumor necrosis factor α, interleukin γ) and Th (interleukin-,-,-) profi le T cells are activated. Cytokines infl uence histocompatibility class II molecules, heat-shock protein-, stimulate the proliferation of fi broblasts, and stimulate fi broblasts to produce GAGs () . Th e predominant data point towards the TSH receptor as the autoantigen in TED (,) . However, it has been suggested that orbital antigen cross reacting with a thyroid antigen might be located in the eye muscle cells (fl avoprotein subunit of mitochondrial succinat dehydrogenase; ). Other orbital autoantigens have been also implicated: calsequestrin (), sarcalumenin () , GS -a novel eye muscle protein () . Most of the anigens (with the notable exception of GS, a cell-membrane antigen) are intracellular and ubiquitus) () . In addition, a Fas mediated apoptosis was demonstrated in extraocular muscle tissue in TED patients () . It has been demonstrated that both Th  (interleukin-, tumor necrosis factor α, interleukin γ) and Th  (interleukin-,-,-) profi le T cells are activated in TED. We therefore measured IF γ and IL- to assess the Th pattern and its relationship to the course of the disease.
Materials and Methods
It has been shown that both Th  (interleukin-, tumor necrosis factor α, interleukin α) and Th  (interleukin-,-,-) profile T cells are activated in the TED. We therefore measured interleukin γ and interleukin - to assess its relationship to the course of the disease.  patients with untreated GO, with proptosis of ≥  mm, and/or impaired eye muscle motility (diplopia) were investigated. All were euthyroid (free T (fT) - pmol/l, total T ,-, nmol/l, thyroid-stimulating hormone (TSH < , mU/l). Cytokine measurements were performed before and after TED treatment. Four patients had decreased visual acuity, reduction of the amplitude of the visually evoked cortical potential, and a central scotoma. Corticosteroids were given as follows: methylprednisolone  mg per day for seven days intravenously, mg for days, than orally , , ,  mg every two days () . Retrobulbar radiotherapy consisted of  fractions of  Gy, in  weeks () . Clinical Activity Score (CAS) quantifi ed the TED activity () . Th e method consists of  items, for each item present  point is given, with the maximal score of . Duration of both TED and GD in months was also noted. Corticosteroid therapy resulted in response of / patients, OI ( patients) given after CS therapy, resulted in a response in all patients, while OD was performed in two patients (after a lack of response to CS treatment, with rapid increase in proptosis, and loss of visual acuity). Both OD treated patients recovered visual acuity and proptosis fell under  Hertel. fT was enzymaticaly determined. Serum samples were kept stored at −°C until use. All samples were measured in duplicate. Highly sensitive, commercially available ELISA were used to measure serum concentrations, IL- (detection limit • pg/ml), and IF γ (detection limit  pg/ml), After descriptive statists was done, t-tests and in case of abnormal distribution, the Mann-Whitney U-test were used. Multivariate ANOVA test for multiple comparisons was also used. T-tests and in case of abnormal distribution, the Mann-Whitney U-test were used. Correlations were calculated with two-tailed Pearson correlation coeffi cients. Changes in serum cytokine concentrations were evaluated with repeated measurement F-tests.
Results
At the start of the disease, free thyroxin was high, TSH low, thyroid ultrasound showed diffuse thyroid enlargement. PTU or MMI resulted in clinical and hormonal remission. Several months after the initiation of the signs of hyperthyroidism, a progression in the ophthalmopathy was observed (Hertel up to mm: normal  mm) while patients were clinically and hormonally euthyroid. Blood was collected in euthyroid state (with TED signs present, before TED treatment) and after  months of treatment (patients without TED and without treatment). CS resulted in response of / patients, OI ( patients) () . Th ose patients require either no treatment or only supportive measures () . Most of the patients present eyelid retraction, followed by proptosis, extra ocular muscular dysfunction. Optic neuropathy is relative rare: only  in the series of Barltey () . Th e most common complaints in their series were diplopia, pain or discomfort, lacrimation, photophobia or blurred vision. However, severe TED forms can lead to optic nerve compression and loss of sight.
Although the defi nition of severe TED is arbitrary, substantial reduction in visual acuity or marked degree of proptosis are generally held to be suffi cient to mark the TED as severe. Soft tissue involvement, although sometimes striking is not a sign of severe TED. Diplopia can markedly hamper the patient's activity. Mourits et al. (, ) proposed nowadays well accepted clinical activity score (CAS) with  diff erent items refl ecting mostly the infl ammatory changes. A point is given to each manifestation and the score results: from  (no activity) to  (highest activity). Th is score can be a good predictor of treatment response () . Th e NO SPECS classifi cation defi nes the numerical score (ophthalmopathy index) of the disease (N no signs or symptoms, O only signs, S soft tissue involvement, P proptosis, E extraocular muscle involvement, C corneal involvement, S sight loss). Th e total eye score gave diff erent weight to various items () . Th yroid Sister Societies () revised the classifi cations mentioned. In general, improvements in the assessment of ocular changes have been done, since the standardization of the assessment is crucial to evaluate the efficiency of the treatment. However, a comprehensive precise and universally accepted evaluation is still lacking. For the purpose of this paper we used the CAS score. For non-severe TED simple measure as change in a sleep position, sunglasses for the photophobia, artifi cial tears or ointments are used, taping the eyelids during the night. Prisms have been benefi cial for the diplopias. β-blocking or guanethidine eye drops are also used with varying success. Smoking withdrawal and reassurance are important. For the initial treatment the majority of the European ophthalmologists preferred glucocorticoid treatment, while  chose OI () . Glucocorticoids have been used for  years, given by oral, local or intravenous route. Oral GC is given in higher doses (- mg/day prednisolone for several months). Recurrence is a frequent event, favorable eff ect is found in - of patients () . Intravenous GS methylpredisolone acetate (,-g) at diff erent intervals has also been used in the last  years. Some authors found that intravenous GC are more effi cient in more severe TED () . Side eff ects are a matter of concern: cushingoid facies, diabetes, depression, osteoporosis, peptic ulcer, hirsuitism, cataract, to name only few of them. To limit the number of recurrences GC should be continued for several months. OI is exerting its effect with its nonspecific anti-infl ammatory eff ect and the high sensitivity of the orbital lymphocytes. It seems that OI reduces the production of GAGs, too. High-energy devices (cobalt unit and linear accelerator) allow better collimation, limited sidescatter and low penumbra. Th e common delivered dose is  grays (Gy) per eye () in  daily doses over a two week period. Th is is thought to reduce the cataractogenetic eff ect of irradiation () . OI is well tolerated, having a transient exacerbation of infl ammatory eye signs and symptoms as main side eff ect. Cataracts, radiation retinopathy are rare. The major concern is the possi- () . To date no secondary tumor after OI was reported. A favorable eff ect of OI can be expected in  of patients () . Some authors used OI with GC () the combination seems to be more eff ective and yields prompt results () . OD is a very eff ective method on the proptosis. Marked proptosis and optic nerve compression were indications for OD. However, there is a shift in the opinion for OD indications. Rehabilitate (cosmetic), severe orbital inflammation, glucocorticoid side effects are also accepted as valid indication for OD (, ) . In general, high incidence of postoperative diplopia (two thirds of the patients) is the major drawback for the OD. It is of note that the unavailability of a skillful orbit surgeon is a major limitation for the indication for OD. Transantral, three-wall coronal orbital surgical approach has been used with various success rates. 
Conclusion
CS treatment is still a mainstream treatment in TED resulting in this series in response in / patients. OI is often an effi cient approach in TED treatment, while OD is required in patients with rapid increase in proptosis and loss of visual acuity is spite of CS and or OI treatment. Serum levels of IL- were not diff erent between the groups of controls and patients. Moreover, its levels were not changed before and after treatment. Th erefore, IL- was not a predictor of the response of treatment, nor of the severity of the disease. Same pattern of serum concentrations was found for the IF γ, rendering him irrelevant as a marker of severity or a predictor of treatment response. In spite of the intensive research of the role of those cytokines in TED no fi rm data so far exist to link them to the important clinical aspects of the disease. As well as for the role of diff erent cytokines, as for the treatment of TED standardization of scores for severity and infl ammation in TED is essential. A precise clinical staging would clarify not only the role of cytokines but the best treatment approach (GC, OI, OD) for individual patient. 
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